Abstract

INTRODUCTION

Renal involvement is common in multiple myeloma and is one of the main causes of morbidity and mortality. The aim of this study was to compare the prognostic effects of some laboratory features, survival, morbidity and mortality in patients with multiple myeloma who were diagnosed with multiple myeloma and developed chronic kidney disease.

METHODS

Patients who were diagnosed with multiple myeloma in the last 5 years and who developed chronic kidney disease or developed chronic kidney disease during their treatment were included in the study, retrospectively.

RESULTS

25 male and 14 female patients were included in the study. The most common complaint was weakness in 27 patients (69.2%). Chronic kidney disease was present in 27 patients at diagnosis, 12 patients had developed chronic kidney disease in the process of treatment. When the patients who developed chronic kidney disease at the time of diagnosis compared with the patients who were not developed; hypercalcemia (p = 0.046) and beta-2 microglobulin levels (p=0.22) were higher in patients with chronic kidney disease. Alkaline phosphatase levels (p = 0.023) and hypercalcemia (p = 0.04) were significantly higher in patients with lytic bone lesions. The mean survival was 6.15 months in 23 patients with who developed chronic kidney disease at the time of diagnosis multiple myeloma, while the mean survival was 30 months in 11 patients with who developed chronic kidney disease in the process of treatment. Average life expectancy at diagnosis; we found that those with chronic kidney disease significantly decreased compared to those without chronic kidney disease (p = 0.027)

DISCUSSION AND CONCLUSION

Renal involvement is common in the course of multiple myeloma and renal involvement is closely related to morbidity and mortality. Early diagnosis and treatment of multiple myeloma will prevent the progression of permanent renal damage and positively affect the progression of the patient.